CVRX CVRx, Inc.
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1235912 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY7.8%
TTM net income YoY-2.4%
TTM EPS YoY-0.5%
Revenue 3-yr CAGR19.7%
Net income 3-yr CAGR—
Margins
Gross margin86.9%
Operating margin-81.9%
Net margin-88.3%
FCF margin-69.7%
EBITDA margin-80.6%
Returns
ROE-172.2%
ROA-53.5%
ROIC (approx.)-299.0%
Asset turnover0.61x
Leverage & solvency
Liabilities / assets84.2%
Debt / equity4.24x
Current ratio6.80x
Interest coverage-8.03x
Cash quality & payout
Operating cash flow / net income0.78x
Accruals ratio-11.7%
Payout ratio—
Capex / revenue0.7%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $13.83M | $15.71M | $14.77M | $16.02M | $14.69M | $13.59M | $12.35M | $15.34M |
| Cost of revenue | $1.83M | $1.98M | $1.89M | $2.20M | $1.94M | $2.14M | $2.04M | $2.57M |
| Gross profit | $12.00M | $13.72M | $12.88M | $13.82M | $12.75M | $11.45M | $10.31M | $12.77M |
| R&D expense | $2.65M | $3.13M | $3.08M | $3.00M | $3.15M | $2.47M | $2.52M | $2.81M |
| SG&A expense | $22.39M | $23.62M | $21.96M | $22.01M | $21.88M | $23.36M | $21.23M | $20.24M |
| Operating income | -$13.04M | -$13.02M | -$12.16M | -$11.18M | -$12.27M | -$14.38M | -$13.44M | -$10.27M |
| Interest expense | $1.61M | $1.58M | $1.55M | $1.42M | $1.48M | $1.47M | $1.46M | $1.52M |
| Pretax income | -$14.16M | -$14.04M | -$13.12M | -$11.94M | -$12.87M | -$14.74M | -$13.77M | -$10.72M |
| Income tax | -$1,000 | $3,000 | $1,000 | -$7,000 | -$3,000 | -$3,000 | -$5,000 | -$71,000 |
| Net income | -$14.16M | -$14.04M | -$13.12M | -$11.93M | -$12.87M | -$14.74M | -$13.77M | -$10.65M |
| EBITDA | -$12.85M | -$12.82M | -$11.96M | -$11.00M | -$12.07M | -$14.18M | -$13.25M | -$10.10M |
| EPS (basic) | -0.52 | -0.53 | -0.50 | — | -0.49 | -0.57 | -0.53 | — |
| EPS (diluted) | -0.52 | -0.53 | -0.50 | — | -0.49 | -0.57 | -0.53 | — |
| Weighted avg. shares (diluted) | 27.25M | 26.52M | 26.36M | — | 26.17M | 26.07M | 25.88M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $58.75M | $64.59M | $72.30M | $75.71M | $85.12M | $95.03M | $102.67M | $105.93M |
| Receivables | $9.59M | $9.40M | $9.10M | $10.66M | $8.21M | $7.15M | $9.01M | $9.27M |
| Inventory | $13.63M | $13.03M | $12.40M | $12.21M | $11.39M | $11.72M | $11.67M | $12.11M |
| Current assets | $85.02M | $89.49M | $96.75M | $101.65M | $107.89M | $116.14M | $126.13M | $129.81M |
| PP&E, net | $1.94M | $2.06M | $2.16M | $2.24M | $2.45M | $2.35M | $2.44M | $2.50M |
| Total assets | $87.61M | $92.28M | $99.73M | $104.79M | $111.33M | $119.56M | $129.59M | $133.41M |
| Current liabilities | $12.51M | $11.12M | $9.49M | $13.32M | $11.22M | $9.69M | $8.51M | $10.76M |
| Long-term debt | $58.66M | $58.57M | $58.49M | $49.51M | $49.45M | $49.39M | $49.33M | $49.27M |
| Total debt | $58.66M | $58.57M | $58.49M | $49.51M | $49.45M | $49.39M | $49.33M | $49.27M |
| Total liabilities | $73.79M | $72.33M | $70.62M | $65.47M | $63.27M | $61.63M | $60.23M | $62.36M |
| Shareholders' equity | $13.82M | $19.95M | $29.11M | $39.32M | $48.05M | $57.93M | $69.36M | $71.06M |
| Net debt | -$91,000 | -$6.01M | -$13.81M | -$26.19M | -$35.67M | -$45.63M | -$53.34M | -$56.66M |
| Shares outstanding | 28.49M | 26.64M | 26.43M | 26.31M | 26.19M | 26.15M | 26.05M | 25.32M |
| Cash flow statement | ||||||||
| Operating cash flow | -$10.90M | -$8.83M | -$12.16M | -$9.76M | -$9.71M | -$7.94M | -$12.77M | -$8.01M |
| Capital expenditure | $98,000 | $112,000 | $122,000 | $68,000 | $295,000 | $103,000 | $114,000 | $52,000 |
| Free cash flow | -$10.99M | -$8.94M | -$12.29M | -$9.83M | -$10.00M | -$8.04M | -$12.88M | -$8.06M |
| Investing cash flow | -$98,000 | -$112,000 | -$122,000 | -$68,000 | -$295,000 | -$103,000 | -$114,000 | -$52,000 |
| Financing cash flow | $5.16M | $1.22M | $8.88M | $410,000 | $103,000 | $392,000 | $9.62M | $13.83M |
| Depreciation & amortization | $200,000 | $200,000 | $205,000 | $185,000 | $200,000 | $200,000 | $184,000 | $178,000 |
| Stock-based compensation | $2.87M | $3.66M | $2.92M | $2.79M | $2.89M | $2.92M | $2.46M | $2.69M |
Free plan shows the latest 8 periods; Pro shows all 26 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.